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BACKGROUND
The United Nations Sustainable Development Goals (UN- 
SDGs) are 17 global goals and 169 targets adopted by all UN 
Member States in September 2015. These targets follow the 
Millennium Development Goals, but have a greater breadth 
of activity and are substantially more ambitious. The goals aim 
to tackle major global challenges by 2030 and focus heavily 
on inequality and climate change. As scientists aiming to 
understand how things work and how we can exploit these 
underlying mechanisms to make the world a better place, 
many of us will feel we have an obligation to try and better 
focus our work in contributing to achieving some of the 
major challenges outlined within the UN- SDGs. Unsurpris-
ingly, health and the environment feature predominantly and 
microbiologists globally are constantly engaged in trying to 
address biological problems through innovative approaches 
and applied scientific method. The ongoing coronavirus 
pandemic aptly exposes the threat that infection disease poses 
to mankind, but also highlights how science can respond 
rapidly and collaboratively to generate novel methods to 
reduce the impact of a new infectious disease. But how do we 
approach such global challenges and what existing capacity do 
we have ready that can be directly applied to the UN- SDGs?
The COVID-19 experience has been a lesson and a severe 
warning shot for the challenges that humanity faces. It is 
increasingly apparent the virus will be with us indefinitely 
and there will be other pandemics in the future for which 
we have to respond with similar haste. But COVID-19 has 
shown us that we have to learn to work as a community and to 
make our research ever more applied to address these longer- 
term threats to mankind, such as pandemics, food security, 
environmental sustainability and antimicrobial resistance 
(AMR). The Microbiology Society recognizes these challenges 
and sees enormous potential in the microbiology research 
community in the UK and Ireland to jointly apply their skills 
in tackling major global issues. Consequently, the Society 
created an expansive project entitled ‘A Sustainable Future’ in 
2019, which is working to define a principal role for microbi-
ology in achieving some key aspects of the UN- SDGs. This is 
an ongoing mission and the scope of the UN- defined goals is 
exceptionally broad and often interlocked; however, engage-
ment with the Microbiology Society’s membership identified 
three specific areas where the expertise of microbiologists in 
the UK and Ireland is particularly relevant. These areas were 
AMR, which is widely recognized as one of the biggest threats 
to humanity; the circular economy, encompassing regenera-
tive approaches aiming to maximize the most efficient use of 
the world’s finite resources; and soil health, which is essential 
for us to sustainably feed an ever- growing global population.
THE WORKSHOP
As opposed to dictating the agenda, as a Society we have 
continuously sought to engage with the community as much 
as possible to direct ideas and to try to focus efforts on the 
key expertise already held within its membership. As a 
component of this project we held a week- long workshop in 
the summer of 2020 to identify challenges and opportunities 
for microbiological research and innovation through inter-
disciplinary collaboration, and interactions with industrial 
partners and social and political institutions in tackling AMR. 
As many of the concepts raised may not be feasible given 
current academic/industrial structures, we also asked what 
more could be done if there were fewer barriers, and what 
interventions would be needed to take the generated ideas 
to the next level.
Given that this workshop was performed during the ongoing 
pandemic, it was conducted online via focus groups chaired 
by recognized experts in each of the defined areas of AMR. 
The meeting chairs for each focus group selected two topic 
clusters that served to frame the discussion around chal-
lenges and opportunities for microbiology in AMR research 
and how we could respond as a community. The clusters for 
each group were: Microbiology research and innovation: (1) 
building a strong and resilient research community and (2) 
disseminating research; Interdisciplinary collaboration: (1) 
structures and funding and (2) managing expectations and 





collaboration and (2) policy, regulations and market; and 
Social and political institution: (1) policy context and (2) 
engagement and culture.
THE DISCUSSIONS
The focus groups were purposely composed of people from 
a range of backgrounds, geographical locations and career 
stages. The discussions were vibrant (occasionally heated) 
and generated a spectrum of opinions that could be directed 
into potential policy documents for how to both utilize and 
adapt the current microbiology research landscape in the UK 
and Ireland. Here, I outline some of the key thoughts and 
perceptions generated during these 90 min discussions. As a 
group we have tried to titrate these into some key concepts 
that may provide a focus into how the microbiology research 
community in the UK and Ireland can contribute to the global 
challenge of antimicrobial- resistant infections.
Microbiology research and innovation
The microbiology research and innovation focus group 
agreed that we must advocate that microbiology is a major 
priority area within the public health system, and ensure that 
microbiology takes a (more) predominant position within 
national and international surveillance systems. Surveillance 
is the principal mechanism for assessing AMR trends and 
the way surveillance is currently structured and integrated 
needs to be vastly improved. Science is commonly focused 
on short- term individual academic achievements; therefore, 
longer term surveillance programmes (i.e. >5 years) are diffi-
cult to establish and maintain but we need more vision and 
sustainability. In Ireland, the task of setting up an efficient 
AMR surveillance system is likely to be directed by the EU. 
The UK, however, will need to develop its own strategy; this 
may prove more challenging out of the EU and will require 
the appropriate funding and direction.
There was a recognition that our knowledge exchange 
mechanisms are outdated and need an overhaul. Publishing 
is the bedrock of scientific research, but it is also a hinder-
ance to information dissemination and career development 
(dependent on author position). The community needs to 
embrace changes in scientific publishing, have less career- 
incentivized approaches to the way we disseminate informa-
tion, and investigate new ways of communicating findings 
outside of this traditional structure. Engaging with a range 
of different expertises will also be key; an AMR innova-
tion and knowledge centre that pulls together capabilities 
from different disciplines is likely to rapidly accelerate the 
AMR research agenda. This could be structured as a virtual 
institute (i.e. such as the Alan Turing Institute) and could be 
championed by the Society and key influencers to act as an 
AMR centre of excellence for identifying and solving specific 
scientific problems around AMR. This type of institute could 
also act as a conduit for changing healthcare policy and facili-
tating new translational interactions with industry, which are 
currently poor.
Whilst the UK/Ireland microbiology research community is 
highly active, it lacks influence at funding organizations. Basic 
microbiology remains integral for our understanding and 
challenging of AMR, and we need to expand our knowledge 
of how antimicrobials work and how they behave in complex 
systems (i.e. systematic off- label effects and interactions with 
the microbiome). AMR research has historically been focused 
on describing and documenting, so microbiologists need to 
better focus their efforts on developing new and innovative 
solutions using routinely generated data.
Interdisciplinary collaboration
The interdisciplinary collaboration focus group considered 
that the AMR community had been largely successful in 
bringing people together from different fields in a compara-
tively short time frame, suggesting there is a strong appetite 
to conduct interdisciplinary research around AMR. The 
AMR research community is fairly well established in the 
UK and needs to be pushed to be broader- thinking and take 
on increasingly ambitious projects. Basic scientific research 
is integral to developing new solutions, but changing behav-
iours, practices and engagement across society needs to be 
performed simultaneously. Therefore, interactions with those 
working in the social sciences, policy and other humanities 
need to be encouraged and facilitated.
AMR research is broad and habitually absorbed into different 
discipline- specific conferences; there are few AMR- specific 
conferences, most of which are focused on the molecular 
aspects of AMR. We as a community should advocate for a 
forum that brings people together from different fields and 
serves to communicate the value of AMR work to those who 
set the scientific agenda and to a wider audience. The UK/
Ireland is in a strong position to lead globally on a series of 
AMR- focused interdisciplinary conferences to overcome 
barriers and provoke more cross- field research. Again, 
encompassing societal change alongside basic science may be 
a novel approach in which to form the nuclei of new collabo-
rations and funding opportunities.
Interdisciplinary research is challenging but if researchers 
are to take advantage of funding calls, they must build rela-
tionships early in order to be prepared when opportunities 
arise. As it stands, scientific funding is again targeted towards 
funding individuals in the short term. There is a need for more 
long- term and ambitious interdisciplinary funding, providing 
sufficient time to establish better interdisciplinary working 
models and collaborations. We (as a community) can afford 
to be more adventurous with the projects we perform, and 
targeted funding is required to test innovative ideas and forge 
better links with industry. Innovation and knowledge centres 
are a potential mechanism for linking academia and industry. 
Such centres create a framework for future collaboration and 
will engage more researchers to participate in interdiscipli-
nary research. PhD programmes in interdisciplinary research, 
aiming to connect academia and industry, could be a mecha-
nism for formulating new interdisciplinary work. There is 
currently a national interdisciplinary PhD programme in the 
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UK, and this mechanism is clearly a cost- effective approach to 
investing in work with potentially high- value returns.
Industry
The industry focus group noted that although early- stage 
innovation is growing, the number of scientists trying to 
develop new antibiotics and diagnostics is surprisingly low. 
Additionally, only a limited number of the major pharmaceu-
tical companies have active infectious disease programmes. 
Consequently, we need to bring industry and researchers 
together as much as possible to facilitate communication 
and develop a common set of challenges and goals for AMR 
research. Ensuring the two communities communicate and 
agree unmet needs, gaps and challenges is paramount. This 
arrangement needs to work both ways; the development of 
novel and transformative technologies is currently performed 
by industry, but academia is likely to contribute greatly if it 
becomes more involved.
Many academic researchers do not know how to interact 
with industry, and better engagement between both sides is 
required. This communication needs to highlight the way 
industry operates and awareness of the policy and regula-
tory environment. Challenge- led initiatives are very impor-
tant, as they allow for industry to be involved early and for 
researchers to work on AMR solutions that are actually 
needed, they respect regulation, and they can be easily scaled. 
For challenge- led research to work, there must be ongoing 
communication throughout the process, from bench to trials.
Researchers and industry need to work with regulators to 
develop innovative infectious disease approaches without 
compromising human safety but perhaps allowing a more 
flexibility in trial design. It was noted that regulators in the 
USA and EU have established AMR advisory groups to inves-
tigate innovate approaches and how these could be accom-
modated. The UK regulatory landscape is overly complex 
and needs to be made clearer to facilitate better engagement. 
Significant policy reforms are happening in countries where 
public health research is in place, such as the WHO innova-
tion in tuberculosis treatment in Eastern Africa. Academic 
funding and industrial funding need a new kind of working 
relationship to enable innovation, and the two groups need 
to renew their commitment to AMR.
There is, however, a key issue: we need significant investment 
in new treatments for patients infected with resistant organ-
isms, but also need to restrict the use of new antimicrobials to 
mitigate resistance. Currently, this model is not viable and the 
antimicrobial ecosystem needs fixing. We need a mechanism 
around this roadblock, and combination treatments may offer 
a way forward. Antibacterials with antivirals can increase 
drug efficacy, and the combination of treatments could be an 
important transformative tool. Combining older technolo-
gies, such as antimicrobial classes that are no longer used, 
with novel innovations, such as monoclonal antibodies, may 
provide revolutionary new approaches in infectious disease 
therapeutics.
Social and political institutions
Given the time at which the workshop was conducted, the 
social and political institutions group initially discussed how 
COVID-19 had the potential to positively and negatively 
impact AMR research. Overall, it was considered that the 
impact of COVID-19 on AMR had, in the short term, been 
negative, with many projects stopping, people being unable 
to work in laboratories and funding being diverted into tack-
ling the pandemic. UK GDP has fallen, and consequently the 
amount of funding available as Official Development Assis-
tance is likely to be substantially reduced in coming years, 
which may impact international AMR programmes. Alter-
natively, COVID-19 will inevitably have knock- on effects 
with respect to AMR from the increased use of antibiotics 
in COVID-19 patients. Additionally, there is now a receptive 
general audience for the impact of infectious disease on human 
populations. Whether there is an increased risk of generating 
AMR as a result of COVID-19 remains to be demonstrated. 
However, it appears that the number of secondary infections 
in COVID-19 patients may have increased antibiotic usage 
in hospitals.
More generally, the panel agreed that a better understanding 
of the ‘one health’ approach and the environmental dimension 
of AMR between humans and animals was needed, rather 
than a focus on environmental health or the impact that the 
environment has on human health. Stewardship programmes 
that promote improved prescribing behaviours have been 
successful over time with significant reductions in antimicro-
bial usage in livestock; lessons from small- scale animal health 
studies could be applied globally and adapted into human 
health care. Again, enhanced surveillance was outlined as a 
necessity, with adaptive culture- independent methods being 
implemented for well- defined programmes.
There was a general agreement that the microbiology commu-
nity could do more to educate the public about AMR and 
how research is being used to tackle it. Microbiology could be 
taught in schools and become a component of the secondary 
school syllabus. Through education the profile of AMR could 
be raised and stressed that it is an urgent threat to human 
health and not a hypothetical problem. AMR may not yet be 
being taken seriously and there is a lack of recognition of how 
AMR contributes to patient death. A potential solution would 
be including AMR- related infection on death certificates 
as a contributing factor. A further possibility would be the 
labelling of antibiotics with information of how these drugs 
affect the patient’s microbiome and increase the personal and 
population risk of drug- resistant infections.
SUMMARY
The current landscape of research into AMR in UK/Ireland 
is broad and highly active, and it is an arena in which we 
can have a major global impact. However, the challenge that 
confronts us is significant and we need to augment some 
aspects of our current AMR research agenda to provide new 
solutions to AMR infections and to deliver the UN- SDGs. The 
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information and the issues presented here were identified and 
discussed by leading experts. These opinions are not exhaus-
tive, but do highlight some of the major issues of the current 
academic structure and outline some potential solutions for 
how we move forward. We need to think beyond publication 
and aim to create more sustainability in our research, with 
better rewards for the truly innovative. Whilst basic research 
is fundamental to understanding the how and why, we also 
need to be more applied, aiming to translate our findings 
into tangible new interventions through better interactions 
with other disciplines and industrial partners. Lastly, AMR 
is going to be an enduring problem and we need longer term 
support to understand and overcome it; the creation of an 
AMR innovation and knowledge centre could provide this 
platform and become the hub of new innovation, interdisci-
plinary research, academic/industry links and policy. AMR is 
one of the biggest healthcare challenges we currently face and 
we as a Society hope our members can rise to the challenge.
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